Evidence map›Paper›PMID 28175304›Full record

ArticleHuman molecular genetics2016

Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis.

Yasuyuki Ohta, Genevieve Soucy, Daniel Phaneuf, Jean-Nicolas Audet, François Gros-Louis, Guy A Rouleau, Hélène Blasco, Philippe Corcia, Peter M Andersen, Frida Nordin and 3 more

Abstract read
In one paragraph

Article in Human molecular genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yasuyuki OhtaResearch Centre of Institut universitaire en santé mentale de Québec, Québec, QC, Canada
Genevieve SoucyResearch Centre of Institut universitaire en santé mentale de Québec, Québec, QC, Canada
Daniel PhaneufResearch Centre of Institut universitaire en santé mentale de Québec, Québec, QC, Canada
Jean-Nicolas AudetResearch Centre of Institut universitaire en santé mentale de Québec, Québec, QC, Canada
François Gros-LouisCHU de Québec Research Center, LOEX Hôpital de l'Enfant-Jésus, Quebec, QC, Canada.
Guy A RouleauMontreal Neurological Institute, McGill University, Montreal, QC, Canada.
Hélène BlascoCentre de Ressources et Compétences SLA (CRCSLA), Federation des CRCSLA Tours-Limoges LITORALS, INSERM U 930, Université François-Rabelais de Tours, France.
Philippe CorciaCentre de Ressources et Compétences SLA (CRCSLA), Federation des CRCSLA Tours-Limoges LITORALS, INSERM U 930, Université François-Rabelais de Tours, France.
Peter M AndersenDepartment of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden
Frida NordinDepartment of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.
Toru YamashitaDepartment of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Koji AbeDepartment of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Jean-Pierre JulienResearch Centre of Institut universitaire en santé mentale de Québec, Québec, QC, Canada

Funding

CIHR
6 · The paper itself

Abstract

Recent genetic studies yielded conflicting results regarding a role for the variant chromogranin B (CHGB)P413L allele as a disease modifier in ALS. Moreover, potential deleterious effects of the CHGBP413L variant in ALS pathology have not been investigated. Here we report that in transfected cultured cells, the variant CHGBL413 protein exhibited aberrant properties including mislocalization, failure to interact with mutant superoxide dismutase 1 (SOD1) and defective secretion. The CHGBL413 transgene in SOD1G37R mice precipitated disease onset and pathological changes related to misfolded SOD1 specifically in female mice. However, the CHGBL413 variant also slowed down disease progression in SOD1G37R mice, which is in line with a very slow disease progression that we report for a Swedish woman with ALS who is carrier of two mutant SOD1D90A alleles and two variant CHGBP413L and CHGBR458Q alleles. In contrast, overexpression of the common CHGBP413 allele in SOD1G37R mice did not affect disease onset but significantly accelerated disease progression and pathological changes. As in transgenic mice, the CHGBP413L allele conferred an earlier ALS disease onset in women of Japanese and French Canadian origins with less effect in men. Evidence is presented that the sex-dependent effects of CHGBL413 allelic variant in ALS may arise from enhanced neuronal expression of CHGB in females because of a sex-determining region Y element in the gene promoter. Thus, our results suggest that CHGB variants may act as modifiers of onset and progression in some ALS populations and especially in females because of higher expression levels compared to males.

Indexed as

AllelesAmyotrophic Lateral SclerosisAnimalsCell Culture TechniquesChromogranin BDisease Models, AnimalDisease ProgressionFemaleGene FrequencyHumansMaleMiceMice, TransgenicMotor NeuronsMutationPolymorphism, Single NucleotideCHGB protein, humanChromogranin BSuperoxide Dismutase-1

Identifiers

PMID28175304
PMCPMC5418737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.